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Background: In the progression towards diabetes, glucolipotoxicity is one of the main causes of pancreatic beta
cell pathology. The aim of this study was to examine the in vitro effects of chronic glucolipotoxic conditions on
cellular responses in pancreatic islets, including glucose and fat metabolism, Calcium mobilization, insulin secretion
and insulin content.
Results: Exposure of islets to chronic glucolipotoxic conditions decreased glucose stimulated insulin secretion
in vitro. Reduced protein levels of Glut2/slc2a2, and decreased glucokinase and pyruvate carboxylase mRNA levels
indicated a significant lowering in glucose sensing. Concomitantly, both fatty acid uptake and triglyceride
accumulation increased significantly while fatty acid oxidation decreased. This general suppression in glucose
metabolism correlated well with a decrease in mitochondrial number and activity, reduction in cellular ATP content
and dampening of the TCA cycle. Further, we also observed a decrease in IP3 levels and lower Calcium
mobilization in response to glucose. Importantly, chronic glucolipotoxic conditions in vitro decreased insulin gene
expression, insulin content, insulin granule docking (to the plasma membrane) and insulin secretion.
Conclusions: Our results present an integrated view of the effects of chronic glucolipotoxic conditions on known
and novel signaling events, in vitro, that results in reduced glucose responsiveness and insulin secretion.
Keywords: Type 2 diabetes, Rat islets, Glucolipotoxicity, Glucose metabolism, Insulin content, Insulin secretionBackground
Type 2 diabetes mellitus (T2DM) is a metabolic disorder in
which pancreatic insulin secretion does not meet the de-
mands of insulin sensitivity [1,2]. Over a period of time, con-
sistently elevated levels of blood glucose and free fatty acids
lead to glucolipotoxicity- mediated pancreatic beta cell dys-
function [3,4]. It is now accepted that elevated glucose levels
are required to mediate the lipotoxic effects, including inhib-
ition of glucose-stimulated insulin secretion (GSIS), im-
paired insulin gene expression and apoptosis [4-8].* Correspondence: m.r.jagannath@connexios.com
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reproduction in any medium, provided the orGSIS involves both glucose oxidation-coupled ATP pro-
duction and the anaplerotic/cataplerotic pathway-mediated
generation of coupling factors that trigger and amplify insu-
lin secretion, respectively [9,10]. Briefly, glucose uptake initi-
ates metabolic pathways in which glucose is first converted
to pyruvate mediated by glucokinase, and then to oxaloace-
tate by pyruvate carboxylase. Mitochondrial oxaloacetate
generates citrate, a cataplerotic signal, which is transported
to the cytosol and then broken down into acetyl-CoA initi-
ating fatty acid synthesis. Acetyl-CoA is subsequently
converted to malonyl-CoA, the concomitant step in fatty
acid synthesis. In pancreatic beta cells, malonyl-CoA in-
hibits carnitine-palmitoyl transferase-1 (CPT-1) blocking
fatty acid oxidation and resulting in the buildup of long-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chronic glucolipotoxic conditions in vitro reduce GSIS.
Rat islets were cultured under normal conditions (control) or with
16.7 mM glucose and 500 μM palmitate for 72 h (GL). Post 72 h, islets
were treated with 2 mM glucose (LG) or 11 mM glucose (HG) for 2 h
and secreted insulin was measured. Data are expressed as mean±SEM
and statistical analysis was performed using the unpaired Student’s
t-test. (*P<0.05, **P<0.01 and ***P<0.001, n=4).
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chain-CoA is thought to be a potential modulator of insulin
secretion stimulating insulin granule docking and exocyt-
osis [11,12]. Glucose metabolism also raises the cytosolic
ATP/ADP ratio, which inhibits the ATP-sensitive potas-
sium channel (KATP) resulting in plasma membrane
depolarization. In response to this, voltage-gated calcium
channels open, causing an influx of extracellular calcium
and exocytosis of insulin granules [13].
Another well-known role of glucose is augmenting insulin
secretion by promoting phospholipase-C (PLC)-mediated
hydrolysis of phosphatidylinositol 4, 5-biphosphate (PIP2)
into diacylglycerol (DAG) and inositol triphosphate (IP3)
[14]. The DAG generated, in turn, activates protein kinase C
(PKC), which is known to maintain insulin exocytosis
[15,16], while IP3 mobilizes calcium from endoplasmic
reticulum stores. The PLC pathway is also known to
upregulate cAMP levels in beta cells, which show glucose-
mediated oscillations that correlate with insulin secretion
[17,18].
Further, glucose is known to increase insulin content
through insulin gene transcription mediated by PDX1 and
MAFa [19]. Under normal conditions, the synthesized insu-
lin is held in readily releasable pools which are transported
to the plasma membrane by the small GTPase, Rab27a and
the SNARE complex for acute calcium-mediated release
[20,21].
Chronic hyperglycemia (glucotoxicity) and hyperlipid-
emia (lipotoxicity) have been known to impair beta cell
function [22,23], and glucolipotoxicity has been defined as
‘the deleterious effects of elevated glucose and fatty acids
on pancreatic beta cell-function and mass’ [24]. Studies by
Kashyap et al. in human subjects have shown that the abil-
ity of the beta cell to increase insulin secretion in response
to fatty acids is a component that may predispose to T2DM
[25]. In accordance with this, animal models for T2DM
show a glucolipotoxicity-mediated dysfunction in multiple
cellular processes involved in insulin secretion [26–27 and
references therein]. In vitro studies have been an important
source of information to understand the molecular basis of
glucolipotoxicity. For example, fatty acid-mediated inhib-
ition of insulin gene transcription, which was identified
in vitro, has been recapitulated in vivo. However, a known
limitation of the in vitro studies in this area of research has
been the varying concentrations of fatty acid used [26].
Here, we used specific concentrations of glucose and
palmitate to study the effects of in vitro chronic gluco-
lipotoxic conditions on intracellular signaling pathways and
cellular processes that mediate glucose responsiveness and
insulin secretion. We confirmed metabolic stress in pancre-
atic islets under these conditions using known stress
markers. We found that chronic glucolipotoxicity impaired
glucose and fat uptake/metabolism in rat pancreatic cells
resulting in lower cellular ATP along with mitochondrialnumber and activity. In agreement with this, IP3 levels were
also reduced as was the calcium mobilized by the IP3 re-
ceptor and the L-type voltage gated calcium channels. Fi-
nally, we found that chronic glucolipotoxicity significantly
decreased insulin secretion by reducing both insulin gene
expression and granule docking to the plasma membrane
in pancreatic islets. Thus, our results present the first inte-
grated view of glucolipotoxicity in vitro linking known and
novel signaling events to reduced glucose sensitivity and in-
sulin secretion.Results
To investigate the effects of chronic glucolipotoxicity on
glucose responsiveness and insulin secretion, we gener-
ated glucolipotoxic conditions in rat pancreatic islets
and the NIT1 beta cell line using 16.7 mM glucose and
500 μM palmitate.Chronic glucolipotoxicity reduces insulin secretion in rat
pancreatic islets
To evaluate the effect of high glucose and fatty acid con-
centrations on insulin secretion, we incubated rat pancreatic
islets as mentzioned above for 72 h (chronic glucolipotoxic
conditions that mimic diabetic pathology [26]); untreated is-
lets were used as control. Under these conditions, we treated
rat pancreatic islets with either low glucose or high glucose
for 2 h to study glucose-stimulated insulin secretion (GSIS)
(Figure 1). In agreement with previous studies [27], in the
presence of high glucose, islet insulin secretion was signifi-
cantly reduced under chronic glucolipotoxic conditions
(Figure 1). We confirmed induction of glucolipotoxicity-
mediated ER stress, oxidative stress and inflammation in
pancreatic islets using known metabolic stress markers
[28,29] (Additional file 1: Figure S1 and Additional file 2:
Figure S2).
To understand the mechanism by which chronic
glucolipotoxic conditions reduce GSIS in vitro, we next
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insulin gene expression and granule docking.
Glucose uptake and metabolism is impaired under
chronic glucolipotoxic conditions
We examined the effect of chronic glucolipotoxic condi-
tions on glucose metabolism in rat pancreatic islets and
NIT1 cells maintaining the same experimental conditions
used in Figure 1. Untreated rat islets and NIT1 cells, re-
spectively were used as controls. We found significant re-
ductions in the mRNA and protein levels of the glucose
transporter, Glut2/Slc2a2 under chronic glucolipotoxic con-
ditions when compared to the untreated control (Figure 2A
and B) [30]. This reduction in Glut2 seen in both NIT-1
cells and rat pancreatic islets (Figure 2B) suggested im-
paired glucose metabolism, which was confirmed by a de-
crease in Glucokinase (Gck) and pyruvate carboxylase (Pc)
mRNA levels (Figure 2C and E) [31-33]. To determine
whether glucose uptake was also affected under chronic
glucolipotoxic conditions, we used a fluorescent glucose
analog, 2-NBDG to monitor glucose uptake. Under chronic




















































Figure 2 In vitro chronic glucolipotoxicity impairs glucose uptake/me
conditions (control) or with 16.7 mM glucose and 500 μM palmitate for 72
Glut2/slc2a2 (A), GCK (C) and PC (E) were measured as described in the m
in both islets and NIT-1 cells by western blotting using anti-Glut2/slc2a2 an
a non-metabolized fluorescent analog as described in the materials and m
(ACLY) inhibitor (Radicicol), post 72 h treatment islets were treated with 11
insulin were measured. Data are expressed as mean±SEM and statistical an
**P<0.01 and ***P<0.001, n=4).glucose uptake (Figure 2D) indicating that both glucose up-
take and metabolism were impaired. Consistent with these
data, NADPH levels decreased and lactate release increased
under chronic glucolipotoxic conditions (Additional file 3:
Figure S3) confirming a dysfunction in glucose metabolism.
The increase in lactate release also suggests that pryuvate,
the end product of glycolysis, was converted into a non-
oxidative metabolite indicating that glucose oxidation is se-
verely impacted under chronic glucolipotoxic conditions.
We next ascertained the link between malonyl-CoA
formation and insulin secretion under chronic gluco-
lipotoxic conditions. To this end, we treated rat islets
cultured in glucolipotoxic conditions with high glucose
and found a decrease in insulin secretion, as expected.
Interestingly, when ATP citrate lyase (ACLY) was
inhibited using radicicol [34], insulin secretion de-
creased further suggesting that ACLY and potentially
the anaplerotic/cataplerotic pathways are involved in
the dysregulation seen in insulin secretion (Figure 2F).
Together, these results suggest that chronic gluco-
lipotoxicity impairs glucose uptake and metabolism








































tabolism. Rat islets or NIT1 cells were cultured under normal
h (GL). Post 72 h, RNA was isolated from islets and the mRNA levels of
aterials and methods. Protein levels of Glut2/slc2a2 (B) were measured
tibodies. Glucose uptake (D) was measured NIT-1 cells using 2-NBDG,
ethods. (F) For insulin secretion in the presence of ATP citrate lyase
mM glucose (HG) with/without 50 μM inhibitor for 2 h and secreted
alysis was performed using the unpaired Student’s t-test. (*P<0.05,
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metabolism
Since chronic glucolipotoxic conditions impaired GSIS, we
next investigated its effect on fatty acid metabolism [35].
We found that mRNA and protein levels of the fatty acid
transporter, cd36 were significantly increased in rat islets
(Figure 3A and B). This increase was observed in both
NIT-1 cells and rat pancreatic islets (Figure 3B) suggesting
increased fatty acid uptake.
To ascertain whether fatty acid uptake is impaired under
chronic glucolipotoxic conditions, we used a BODIPY dye, a
non-metabolized fluorescently labelled fatty acid analog. We
observed a three-fold increase in fatty acid uptake
under chronic glucolipotoxic conditions (Figure 3C) in-
dicating that along with CD36 mRNA and protein
levels, fatty acid uptake was also impaired. Further, we also
found fat metabolism to be impaired under chronic
glucolipotoxic conditions as seen from the four-fold
increase in triglyceride levels in the pancreatic beta cell
line, NIT-1 (Figure 3D). This was validated by a reduc-
tion in fatty acid oxidation studied by measuring the
mRNA levels of PPARa (Figure 3E). We confirmed that
in vitro chronic glucolipotoxicity generated metabolic





























































Figure 3 Chronic glucolipotoxic conditions in vitro impair fatty acid u
normal conditions (control) or with 16.7 mM glucose and 500 μM palmitat
levels of cd36 (A) and PPARα (E) were measured as described in the mater
(B) were measured by western blotting using anti-CD36 antibodies. Fatty a
BODIPY dyes, a non-metabolized fluorescent labelled fatty acid analog as d
post incubation cells were lysed and cellular triglyceride levels were estima
mean±SEM and statistical analysis was performed using the unpaired Studstress [28,29] (Additional file 2: Figure S2A). Taken to-
gether, these data showed that chronic glucolipotoxic con-
ditions impaired both glucose and fatty acid uptake and
metabolism.
Mitochondrial number/activity and cytosolic ATP levels
are reduced under chronic glucolipotoxic conditions
Since a primary outcome of glucose metabolism is ATP
synthesis from mitochondria [27], we investigated the ef-
fect of chronic glucolipotoxic conditions on mitochondrial
DNA copy number/activity and cellular ATP. Under
chronic glucolipotoxic conditions, mtCox1 levels were sig-
nificantly reduced in rat pancreatic islets along with a de-
crease in glucose-mediated cellular ATP (Figure 4A and B)
suggesting a reduction in mitochondrial number. To as-
certain the impact of decreased mtCox1 copy number on
mitochondrial function under chronic glucolipotoxic con-
ditions, we measured activity of succinate dehydrogenase-
a critical enzyme in both the citric acid cycle and the
mitochondrial respiratory chain. We found that under
chronic glucolipotoxic conditions, succinate dehydrogen-
ase activity decreased by ~50% (Figure 4C). This reduction
in mitochondrial activity was further studied by measuring



















ptake/ metabolism. Rat islets and NIT1 cells were cultured under
e for 72 h (GL). Post 72 h, RNA was isolated from islets and the mRNA
ials and methods. Protein levels of CD36 in both islets and NIT-1 cells
cid uptake (C) was measured in NIT-1 cells using green-fluorescent
escribed in the materials and methods. For triglyceride estimation,
ted and normalized to total protein content (D). Data are expressed as










































































Figure 4 Chronic glucolipotoxicity in vitro reduces mitochondrial number and activity. Rat islets and NIT1 cells were cultured under normal
conditions (control) or with 16.7 mM glucose and 500 μM palmitate for 72 h (GL). Post 72 h, total DNA was isolated from islets and mitochondrial
DNA copy number (A) was estimated by assessing mtCox1 (mitochondrial gene) copy number normalized to HPRT (nuclear gene). Post
treatment, islet ATP levels (B) were estimated after 60min induction with 11 mM (HG) as described in the materials and methods. Both SDH
activity in NIT-1 cells (C) and amino acids (5 mM of leucine and 5 mM of glutamine) mediated insulin secretion (D) in islets were measured as
described in the materials and methods. VC is vehicle control with 2 mM glucose and without amino acids. Data are expressed as mean±SEM
and statistical analysis was performed using the unpaired Student’s t-test. (*P<0.05, **P<0.01 and ***P<0.001, n=4).
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chronic glucolipotoxic conditions reduced insulin secre-
tion indicating an overall suppression of the TCA cycle
(Figure 4D).
These data present the first line of evidence linking a
decrease in cellular ATP to a reduction in mitochon-
drial number and activity under chronic glucolipotoxic
conditions.
An increase in cytoplasmic calcium is required for insulin
secretion under chronic glucolipotoxic conditions
Since chronic glucolipotoxicity lowered GSIS and glu-
cose metabolism, we investigated its effects on IP3 and
cytosolic calcium, known signaling mediators of insu-
lin secretion [13,17]. We detected a modest decrease in
IP3 upon culturing rat pancreatic islets under chronic
glucolipotoxic conditions (Figure 5A). Next, we investi-
gated intracellular calcium dynamics under chronic
glucolipotoxic conditions in NIT-1 cells; cells cultured
in 5mM glucose were used as control. Subsequently,cells were treated with either low or high glucose and
cytosolic calcium was measured. In control cells, high
glucose enhanced cytosolic calcium mobilization when
compared to the low glucose treatment. Interestingly, this
effect of high glucose on cytoplasmic calcium was lost
under glucolipotoxic conditions (Figure 5B and C).
As further confirmation, we ascertained whether
L-type voltage gated calcium channels mobilized cal-
cium under glucolipotoxic conditions by studying in-
sulin secretion in the presence or absence of the
L-type channel inhibitor, Nitrendipine, NTD [37]. As
reported earlier, we detected a decrease in high glucose-
mediated secretion in the presence of NTD (Additional
file 4: Figure S4A). In a similar assay, upon using the
IP3 receptor inhibitor, 2-aminoethyldiphenyl borate
(2-APB) [38], we found that endoplasmic reticulum
calcium mobilization was also required for insulin se-
cretion (Additional file 4: S4B). In summary, chronic
glucolipotoxic conditions impaired IP3 levels and cyto-
solic calcium release.
A B C
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Figure 5 Chronic glucolipotoxicity in vitro impairs calcium release. Rat islets and NIT-1 cells were cultured under normal conditions (control)
or with 16.7 mM glucose and 500 μM palmitate for 72 h (GL). Post 72 h, islet IP3 levels (A) were estimated in the presence of 11 mM (HG) as described
in the materials and methods. For cytosolic calcium mobilization assay (B and C), post treatment NIT-1 cells were loaded with Fluo-3AM calcium
indicator dye for 1 h. After washing the cells, they were treated with either low (2.5 mM) or high (16.7 mM) glucose and the change in fluorescence
was estimated as described in the materials and methods. Data are expressed as mean±SEM and statistical analysis was performed using the unpaired




















Figure 6 Chronic glucolipotoxic conditions in vitro reduce
intracellular insulin content. Rat islets were cultured under normal
conditions (control) or with 16.7mM glucose and 500 μM palmitate
for 72 h (GL). Post 72 h, islets were treated with 2 mM glucose (LG)
or 11 mM glucose (HG) for 2 h. Islets were washed, lysed and islet
insulin content was measured. Data is expressed as mean±SEM and
statistical analysis was performed using the unpaired Student’s t-test.
(*P<0.05, **P<0.01 and ***P<0.001, n=4).
Somesh et al. BMC Cell Biology 2013, 14:31 Page 6 of 11
http://www.biomedcentral.com/1471-2121/14/31Insulin synthesis and intracellular insulin content are
reduced under chronic glucolipotoxic conditions
Calcium and cAMP are known to influence insulin gene
expression through Pdx1 [39,40]. As reported previously
[19], Pdx1 and insulin (Ins2) mRNA levels were reduced
under chronic glucolipotoxic conditions (Additional file 5:
Figure S5A and B). Thus, chronic glucolipotoxicity not
only mediates its effects on GSIS by impairing glucose me-
tabolism but also a down-regulation of insulin gene tran-
scription. Lastly, we ascertained whether changes in insulin
synthesis and glucose metabolism influenced insulin con-
tent (Figure 6). To test this, we treated rat islets (as in
Figure 1) and observed a significant decrease in islet insulin
content under chronic glucolipotoxic conditions (Figure 6).
Thus, chronic glucolipotoxicity significantly affects overall
glucose responsiveness through glucose metabolism, cal-
cium release and insulin gene expression.
Insulin granule docking is reduced under chronic
glucolipotoxic conditions
In animal models of T2DM, the small GTPase, Rab27a
is known to be downregulated leading to decreased insu-
lin granule docking to the plasma membrane, thereby
lowering insulin secretion [41]. In addition, insulin re-
lease at the fusion pore is also known to be impaired in
diabetic animal models resulting in defects in exocytosis
and release [42].
Here, we found that Rab27a mRNA significantly de-
creased under chronic glucolipotoxic conditions in both
pancreatic islets and NIT1 cells (Figure 7A and Additional
file 5: Figure S5C) suggesting a decrease in the readily re-
leasable pool of insulin granules docked to the plasma
membrane. To confirm this, we treated rat islets with po-
tassium chloride (KCl), a membrane-depolarizing agent
known to release insulin vesicles docked to the plasmamembrane [43]. As expected, we found a significant de-
crease in docked insulin granules under chronic gluco-
lipotoxic conditions when compared to control islets
(Figure 7B). These data show that chronic glucolipotoxicity
reduces insulin secretion through its effects on insulin syn-
thesis and transport in addition to glucose uptake/metabol-
ism and cystosolic calcium mobilization.
Taken together, these data provide the first, integrated
in vitro view of known dysfunctional cellular mechanisms in
chronic glucolipotoxic conditions, while identifying novel
events such as the glucolipotoxicity-mediated reduction in








































Figure 7 In vitro chronic glucolipotoxicity reduces insulin docking and exocytosis. Rat islets were cultured under normal conditions
(control) or with 16.7 mM glucose and 500 μM palmitate for 72 h (GL). Post 72 h, RNA was isolated from islets and the mRNA levels of Rab27a
(A) were measured as described in the materials and methods. For measurement of insulin granule docking (B) following incubation under chronic
glucolipotoxic conditions, islets were treated with LG (2.5 mM glucose) with or without 30 mM KCl for 30 min. Secreted insulin was measured as
described in the materials and methods. Data are expressed as mean±SEM and statistical analysis was performed using the unpaired Student’s
t-test. (*P<0.05, **P<0.01 and ***P<0.001, n=4).
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Despite intensive research, information about the mechan-
ism of action and intracellular signaling pathways acti-
vated by glucolipotoxicity remains limited. Such an
understanding has clinical relevance since the ability of
the beta cell to increase insulin secretion in response to
fatty acids is thought to be a predisposing factor for
T2DM [25]. In vitro studies have been important to gain a
mechanistic understanding of glucolipotoxicity but have
not allowed a complete view of glucolipotoxicity-mediated
cellular dysregulation due to variations in the concentra-
tions of fatty acids used [24]. This study systematically
evaluates specific in vitro glucolipotoxic conditions linking
their effect to multiple cellular processes involved in insu-
lin secretion and glucose responsiveness including glucose
uptake/metabolism, fatty acid uptake/metabolism, cellular
energetics, insulin synthesis, secretion and transport; and
calcium dynamics.
We used 16.7 mM glucose and 500 μM palmitate in this
study after evaluating multiple concentrations for their ef-
fect on metabolic stress and cell death (unpublished obser-
vations). Under these conditions, we confirmed metabolic
stress in pancreatic islets and the NIT1 pancreatic beta cell
line as seen by the strong induction of ER stress, oxidative
stress and inflammation. As previously reported [27], these
conditions also led to cell death as seen by the significant
increase in caspase-3 activity (Additional file 2: Figure S2B).
Under chronic glucolipotoxic conditions in vitro, we
found that insulin content and GSIS were lowered in rat
pancreatic islets. Further, glucose and fat metabolism were
impaired in islets correlating with the decrease in mito-
chondrial number/activity and cellular ATP levels. Chronic
glucolipotoxicity reduced cytosolic calcium levels by de-
creasing calcium mobilization mediated by ITPR.
Based on our findings, we propose a model for the ef-
fect of chronic glucolipotoxicity on the pancreatic betacell (Figure 8). Extended exposure to high glucose and
palmitate concentrations leads to a) suppression of gly-
colysis resulting in reduced cellular ATP and a dampening
of the TCA cycle, b) reduction in mitochondrial DNA
copy number and activity, c) reduction in PLC-IP3 signal-
ing leading to reduced calcium mobilization, insulin tran-
scription and granule docking, and d) a decrease in insulin
transcription and synthesis.
Our in vitro findings recapitulated data from previous
glucolipotoxic studies in animal models showing an impact
on glucose metabolism, calcium dynamics and insulin se-
cretion/content [24,44]. For example, we detected an in-
crease in CD36 expression under glucolipotoxic conditions
that correlated with enhanced triglyceride accumulation
and reduced GSIS. These findings concur with data from
cd36-null mouse models and over-expression studies in
INS cell lines [45,46] further validating the in vitro condi-
tions used in our study.
We found it interesting that chronic glucolipotoxic con-
ditions impacted multiple cellular processes including in-
sulin synthesis, content and docking. On the basis of our
results, we speculate that chronic glucolipotoxicity im-
pacts insulin content most severely compared to insulin
gene transcription, docking and secretion. Future studies
will be required to get a more complete understanding of
the same.
A key finding in our study is the influence of
glucolipotoxicity on mitochondrial number/function. This
is in line with the notion that enhanced insulin secretion
may require an overall increase in mitochondrial activity/
number as opposed to an isolated increase in an aspect of
mitochondrial metabolism [47,48]. In this study, we also
detected a decrease in insulin granule docking/release
under glucolipotoxic conditions indicative of a reduction in
the readily releasable pool of insulin, which may have a
bearing on the first-phase insulin secretion [43]. Further
TAG 
FA uptake 

















PLC – IP3 
ATP 
Citrate shuttle 






Figure 8 Model for impact of in vitro chronic glucolipotoxicity on cellular processes in pancreatic beta cells. Model describes the
signaling pathways involved in glucose and fat metabolism with focus on their coupling to insulin secretion. We found that under chronic
glucolipotoxic conditions in vitro, multiple signaling events involved in glucose and fat metabolism are dysregulated leading to impaired insulin
synthesis, content and secretion. The effects of chronic glucolipotoxic conditions on the signaling events involved are shown using upward
arrowheads (representing an increase) and downward arrowheads (representing a decrease). In the model, arrows indicate activation and blunt
arrows indicate inhibition.
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tween docking/exocytosis and the DAG-PKC pathway in
more detail.
Increasing insulin secretion is an intensely pursued thera-
peutic strategy in T2DM. This study yields in vitro assay
conditions that can be used to evaluate anti-diabetic agents,
specifically insulin secretagogues, currently in development
for their impact on glucolipotoxicity-mediated dysregulation.
Importantly, an understanding of glucolipotoxicity-mediated
cellular dysfunction may yield novel points of therapeutic
intervention (i.e., targets/target classes) that hold promise in
T2DM treatment. Thus, our study has potential to facilitate
an improved understanding of pancreatic beta cell patho-
physiology in T2DM.
Conclusions
Chronic glucolipotoxic conditions comprising high glucose
and fatty acid resulted in various defects in key cellular ma-
chineries. Glucose sensing machinery involved in uptake
and glucose metabolism for insulin secretion was reduced
whereas fat uptake and triglyceride storage was increased.
Defects in mitochondrial number and activity along with
reduced ATP levels were observed under glucolipotoxic
conditions. Similarly, beta cells showed increased ER stress,inflammation and apoptosis together with impaired calcium
homeostasis. These defects occurred in conjunction with de-
creased insulin synthesis, insulin vesicle transport, docking
and glucose-dependent insulin secretion. Our data provide a
first integrated view of beta cell defects across multiple levels
under chronic glucolipotoxic conditions.
Methods
RNA isolation, reverse transcription and quantitative real
time polymerase chain reaction (qPCR)
Isolation and preparation of rat islets has been described in
detail in Additional file 6 (supplementary methods). All ani-
mal studies and protocols were approved by the Institu-
tional Animal Ethics Committee (IAEC) of Connexios Life
Sciences Pvt Ltd. Post 72 h of incubation, total RNA was
isolated and 1 μg of total RNA was used to generate cDNA
(ABI, USA). Gene expression was measured using SYBR
Green PCR Master Mix (Eurogenetic, Belgium). Gene
primers for Slc2a2/Glut2, Gck, Pc, CD36, PPARα, Pdx1,
Ins2, Rab27a, Il1β, Nos2a and Actb were based on mRNA
sequences from the GenBank nucleotide database and
designed in-house. Actb was used as an internal control.
The primer sequence for the above gene markers are given
in the Additional file 6 (supplementary methods).
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Islets were isolated from rats (details in Additional file 6)
and cultured in 90 mm petri-plates with RPMI 11 mM glu-
cose and 10% FBS and penicillin streptomycin, in the pres-
ence or absence of 16.7 mM glucose and 500 μM palmitate
for 72 h/37°C/5% CO2. Size-matched islets were isolated
and transferred into 24-well plates containing 1ml KRBH
(2.5 mM glucose)/well, and incubated at 37°C/5% CO2 for
1h. After removing the KRBH buffer, the islets were in-
duced in KRBH buffer (250μl/well) at 37°C/5% CO2 for 2 h
at indicated glucose concentrations with/without the speci-
fied pharmacological inhibitors. Inhibitors were used at the
following concentrations: Radicicol (50 μM; Sigma) and
Nitrendipine (5 μM; Sigma); 2-APB (10 μM, Sigma). Se-
creted insulin was measured in KRBH buffer using ELISA
(Mercodia) as per manufacturer’s instructions. To measure
insulin secretion in the presence of TCA cycle precursors,
islets were prepared as above and treated with 5 mM leu-
cine and 5 mM glutamine-containing KRBH for 2 h; 2 mM
glucose without amino acids was used as a control. Islet ly-
sates were used to measure intracellular insulin content
and insulin levels were presented as ng insulin/islet.
Western blotting
NIT1 (ATCC) cells or rat islets were cultured with
5.5 mM glucose (control) with or without 16.7 mM glu-
cose and 500 μM palmitate (GL) for 72 h. After incuba-
tion, cells or islets were lysed and total proteins were
resolved by SDS-PAGE followed by transfer to nitrocellu-
lose membrane. Protein expression and phosphorylation
was measured using
Antibodies against Glut2, CD36 (Abcam), BiP, CHOP,
p-eIF2a or β-actin (Cell Signaling Technology) and HRP
conjugated secondary antibody (Bio-Rad). The protein
specific signals were detected using chemiluminescence
substrate (Pierce) and were quantified using Image-J
software (NIH).
Measurement of glucose uptake
NIT1 cells were cultured with 5.5 mM glucose (control)
with or without 16.7 mM glucose and 500 μM palmitate
(GL) for 72 h. Post 72 h, cells were washed and incubated
in glucose-free medium at 37°C for 30 min followed by
incubation with 50 μM of 2-NBDG (2-(N-(7-Nitrobenz-
2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose; Invitrogen)
for 15min. After lysis, 2-NBDG uptake was measured at
465 nm excitation/540 nm emission, and normalized to
total cellular DNA as measured using bis-benzamide at
360 nm.
Measurement of fatty acid uptake
NIT1 cells were cultured with 5.5 mM glucose (control)
with or without 16.7 mM glucose and 500 μM palmitate
(GL) for 72 h. Post 72 h, cells were washed and incuba-ted in glucose-free medium at 37°C for 30 min followed
by incubation with 1 μM of green-fluorescent BODIPY
dyes (Molecular Probes) for 10 min. Cells were washed
and incubated with 0.4% trypan blue for 5 min to
quench any excess dye. Subsequently, cells were washed,
lysed and BODIPY uptake was measured at 485 nm exci-
tation/528 nm emission and normalized to total cellular
proteins as measured using the Bradford assay (Bio-Rad).
BODIPY uptake was represented as % of uptake under
control condition.
Estimation of triglycerides
NIT1 cells were cultured with 5.5 mM glucose (control)
with or without 16.7 mM glucose and 500 μM palmitate
(GL) for 72 h. After incubation, cells were washed with
PBS and lysed. Total cellular protein was estimated
using the Bradford assay (Bio-Rad) and triglyceride levels
were estimated using an enzymatic assay (DiaSys) as per
manufacturer’s instructions. TAG levels were normalized
to cellular protein levels.
Estimation of mitochondrial DNA copy number
Freshly isolated rat islets were cultured under control or
glucolipotoxic conditions for 72 h. Post 72 h treatment, is-
lets were harvested in digestion buffer (Tris-10mM, pH8.0,
EDTA-1 mM, NaCl-5 mM, SDS-1% and RNAse-A-10 mg/
ml) followed by a phenol-chloroform extraction and etha-
nol precipitation of total DNA. 5 μg DNA was used for
quantitative real time PCR. Mitochondrial cytochrome C
oxidase 1 (mtCox1) copy number was measured and nor-
malized to nuclear DNA using hypoxanthine guanine
phosphoribosyltransferase (HPRT).
Measurement of islet ATP
Rat islets were cultured as in the insulin secretion assay.
Islets were incubated in the KRBH buffer containing 2.5 mM
glucose for 1h followed by induction with 11 mM glucose
(HG) for 1h. After 1 h of incubation, islets were lysed and
ATP levels were estimated as per manufacturer’s instruc-
tions (ATP determination kit, Invitrogen).
Measurement of succinate dehydrogenase activity
NIT1 cells were cultured in 5.5 mM glucose (control) with
or without 16.7 mM glucose and 500 μM palmitate (GL)
for 72 h. After incubation, cells were washed and incubated
in 100 mM potassium phosphate buffer containing 50 mM
sucrose, 10 mM sodium azide, 500 mM sodium succinate
and 8 mM INT (Iodonitrotetrazolium chloride; Sigma) for
2 h. Cells without sodium succinate were used as a negative
control. After 2 h at 37°C, INT was dissolved in DMSO
and estimated at 644 nm. The difference in absorbance
with/ without succinate was calculated, normalized to total
cellular protein and represented as % control SDH activity.
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Freshly isolated rat islets were cultured under normal con-
dition (control) or under glucolipotoxic condition (GL) for
72 h. Islets were then washed and incubated in KRBH
containing 2.5 mM glucose for 1h followed by treatment
with HG for 5 min. IP3 levels were measured in the lysate
using an immunoassay kit (Cusabio IP3 estimation kit).
Estimation of calcium mobilization
NIT1 cells were cultured with 5.5 mM glucose (control)
with or without 16.7 mM glucose and 500 μM palmitate
(glucolipotoxic) for 72 h. After incubation, cells were
washed with calcium-free KRBH buffer followed by in-
cubation at 37°C for 1 h in Fluo-3-AM calcium indicator
fluorescent dye (Invitrogen). Cells were then induced
with either low (2.5 mM) or high (16.7 mM) glucose and
the fluorescence was measured at 485 nm. The baseline
reading was established by reading fluorescence for 1 mi-
nute (from t=0 to t=1 minute) at 6 s intervals. The indi-
cated glucose concentrations were added at t=1 minute.
After mixing for 5 s, the final reading was taken for 3 mi-
nutes (from t=1 minute to t=4 min) at 6 s intervals.
Exocytosis of docked insulin granules
Islets were cultured as in the insulin secretion assay,
washed and incubated in KRBH buffer containing 2.5 mM
glucose for 1h. Islets were treated with low glucose alone
(2 mM) with/without 30 mM KCl in KRBH for 30 min
followed by estimation of secreted insulin in the buffer.
Statistical methods
Data are expressed as mean±SEM and significance was
calculated using the unpaired Student’s t-test. * indicates
p<0.05; ** indicates p<0.01; *** indicates p<0.001 com-
pared to the respective control. Unless mentioned other-
wise, n=4 across experiments. Miscrosoft Excel was used
for statistical analyses.
Additional files
Additional file 1: Figure S1. Chronic glucolipotoxic conditions increase
inflammatory cytokines gene expression and cellular stress in pancreatic
β-cells. Rat islets or NIT1 cells were cultured under normal conditions
(control) or with 16.7 mM glucose and 500 μM palmitate for 72 h (GL).
Post 72 h, RNA was isolated from islets and the mRNA levels of IL1b (A)
and Nos2a (B) were measured as described in the materials and
methods. Both ROS (C) and nitric oxide (D) levels were estimated in NIT1
cells as described in the Additional file 6. Data are expressed as mean
±SEM and statistical analysis was performed using the unpaired Student’s
t-test. (*P<0.05, **P<0.01 and ***P<0.001, n=4).
Additional file 2: Figure S2. Chronic glucolipotoxic conditions increase
endoplasmic reticulum stress and apoptosis in pancreatic β-cells. NIT1
cells were cultured under normal conditions (control) or with 16.7 mM
glucose and 500 μM palmitate for 72 h (GL). Post 72 h, changes in ER
stress markers (A) were analyzed using anti-CHOP, anti-BiP and phospho-
specific EIF2a antibodies; β-actin was used as the internal control. Both
Caspase-3 activity (B) and cell viability (MTT assay) were measured inNIT1 cells as described in the Additional file 6. Data are expressed as
mean±SEM and statistical analysis was performed using the unpaired
Student’s t-test. (*P<0.05, **P<0.01 and ***P<0.001, n=4).
Additional file 3: Figure S3. Glucose metabolism is impaired under
glucolipotoxic condition. NIT1 cells were cultured under normal
conditions (control) or with 16.7 mM glucose and 500μM palmitate for
72 h (GL). Post 72 h, cells were lysed and cellular NADPH levels were
measured (A) and culture medium was used for the estimation of lactate
levels (B). Data are expressed as mean±SEM and statistical analysis was
performed using the unpaired Student’s t-test. (*P<0.05, **P<0.01 and
***P<0.001, n=3-4).
Additional file 4: Figure S4. Cytoplasmic calcium increase is required
for insulin secretion under glucolipotoxic condition. Rat islets were
cultured under normal conditions (control) or with 16.7 mM glucose and
500 μM palmitate for 72 h (GL). Post 72 h, islets were treated with 11 mM
glucose (HG) alone or with inhibitors (5 μM Nitrendipine and 10 μM
2-APB) for 2 h and secreted insulin was measured as described in the
materials and methods. Data are expressed as mean±SEM and statistical
analysis was performed using the unpaired Student’s t-test. (*P<0.05,
**P<0.01 and ***P<0.001, n=4).
Additional file 5: Figure S5. Chronic GL conditions reduce insulin
synthesis and vesicle transport. Rat islets or NIT1 cells were cultured
under normal conditions (control) or with 16.7 mM glucose and 500 μM
palmitate for 72 h (GL). Post 72 h, RNA was isolated from both islets and
cells. The mRNA levels of PDX1 (A) and Insulin (B) were measured in
islets and Rab27a levels (C) in cells were measured as described in the
materials and methods. Data are expressed as mean±SEM and statistical
analysis was performed using the unpaired Student’s t-test. (*P<0.05,
**P<0.01 and ***P<0.001, n=4).
Additional file 6: Supplementary methods.
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